Browsing Category
Pharma Industry News
4739 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why Nordic Capital and Permira’s DKK19bn offer for Bavarian Nordic failed despite board approval
Despite a premium offer and board backing, the Nordic Capital–Permira bid for Bavarian Nordic fell short. Explore why the takeover failed and what lies ahead.
Jupiter Neurosciences secures FDA green light for Phase 2a clinical trial of JOTROL in Parkinson’s disease
Find out how Jupiter Neurosciences’ FDA-approved JOTROL Phase 2a trial could reshape Parkinson’s treatment and redefine the biotech innovation race.
Viking Therapeutics’ GLP-1/GIP dual agonist VK2735 impresses at ObesityWeek 2025 with sustained weight-loss efficacy
Find out how Viking Therapeutics’ VK2735 is redefining obesity treatment with sustained clinical results — see what this breakthrough means for patients and investors today!
Investors eye Plus Therapeutics after promising ReSPECT-LM results and FDA fast-track push for REYOBIQ in brain metastases
See how Plus Therapeutics’ REYOBIQ delivered >75 percent benefit and no toxicity in its ReSPECT-LM trial—discover what this means for CNS cancer treatment and investors.
Palatin Technologies to raise $15.8m in public offering; NYSE relisting expected Nov 12
Palatin Technologies regains NYSE American compliance and secures $15.8M for its oral MC4R obesity drug. Find out how the relisting and IND impact its biotech trajectory.
FDA approves JNJ’s CAPLYTA for depression: Is this a new hope for MDD remission?
Johnson & Johnson secures FDA approval for CAPLYTA in major depressive disorder. Find out how this expands safe treatment options for difficult-to-treat depression.
Schrödinger (NASDAQ: SDGR) trims 2025 software growth forecast to 8%–13% despite strong Q3 results
Find out why Schrödinger’s revised software guidance may mark a shift in pharma AI strategy, with delayed deals and a pivot to operational efficiency.
Dynavax (NASDAQ: DVAX) targets 60% U.S. hepatitis B market share by 2030 amid COVID vaccine deal, $100m buyback
Dynavax targets 60% of U.S. hepatitis B vaccine market by 2030, expands COVID-19 pipeline, and authorizes $100M buyback. Read what this signals for investors.
Vir Biotechnology just finished its HDV Phase 3 enrolment early—here’s why investors are watching
Vir Biotechnology completes ECLIPSE 1 trial enrolment early and secures a funding runway into mid-2027. See what this means for its hepatitis delta ambitions.
atai Beckley emerges as new global leader after atai Life Sciences and Beckley Psytech complete strategic merger in mental-health biotech
Find out how atai Life Sciences and Beckley Psytech’s merger to form atai Beckley is reshaping psychedelic biotech and transforming depression treatment.